title: A comparison of clinical use of fluticasone propionate and beclomethasone dipropionate in pediatric asthma.
abstract: Inhaled steroids play a very important role in the prevention and treatment of asthma. Previous studies indicated that fluticasone propionate (FP) had low bioavailability and high local potency. However, the laboratory data in these studies were not obtained among Taiwan population. It is very important that native data should be established. Thus a 12-week research program was designed, involving 77 patients, 51 for FP group and 26 for beclomethasone dipropionate (BD) group. The objects were victims of moderate to severe asthma and their age ranged from 4 to 14 years old. An open, comparative and randomized method was adopted. Except for the 4-week-later daytime symptom score(P = 0.033, BD group was better), no other significant differences were found between the two groups in the symptom score improvement(P > 0.05). All the P-values for the daytime & night-time scores were lower than 0.001, which means obvious improvement after treatment in both groups. P-value for PEF improvement was 0.003 after 4 weeks (BD group was better) and 0.943 after 8 weeks; for FEV1 improvement, it was 0.005 after 4 weeks(BD group was better) and 0.252 after 8 weeks; and for FEV1/FVC improvements, it was 0.067 after 4 weeks and 0.097 after 8 weeks. There was no statistic significance in total eosinophil count (TEC), IgE, eosinophil cationic protein (ECP) serum level changes after 4 or 8 weeks. Adverse effects were all anticipated and no statistic significance showed up, either, between the two groups or in the cortisol levels (P > 0.05). In conclusion, native data indicated that the potency of 100 micrograms of FP was equal to that of 200 micrograms of BD and that few side effects were noted in FP group. It is recommended that this drug be introduced for clinical use.
authors.affiliation: Department of Pediatrics, Veteran General Hospital-Kaohsiung, No. 386, Ta-Chung 1st Road, Kaohsiung, Taiwan.
authors.forename: B R
authors.initials: BR
authors.lastname: Nong
authors.forename: Y F
authors.initials: YF
authors.lastname: Huang
authors.forename: K S
authors.initials: KS
authors.lastname: Hsieh
authors.forename: Y Y
authors.initials: YY
authors.lastname: Huang
authors.forename: C F
authors.initials: CF
authors.lastname: Huang
authors.forename: S L
authors.initials: SL
authors.lastname: Chuang
authors.forename: C C
authors.initials: CC
authors.lastname: Liu
mesh_terms: D000293:Adolescent; D000730:Androstadienes / Q000009:adverse effects / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000097:blood / Q000188:drug therapy*; D001507:Beclomethasone / Q000009:adverse effects / Q000627:therapeutic use*; D001798:Blood Proteins / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D047091:Eosinophil Granule Proteins; D004804:Eosinophils / Q000502:physiology; D005260:Female; D000068298:Fluticasone; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D008297:Male; D012260:Ribonucleases
chemical_list: D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D007073:Immunoglobulin E; D000068298:Fluticasone; D012260:Ribonucleases; D001507:Beclomethasone